6.4. summary evidence guidelines stratification non-muscle-invasive bladder cancer. summary evidencelethe eau nmibc 2021 scoring model risk tables predict short- long-term risks disease progression individual patients primary nmibc using either 1973 2022 classification system (see section 6.1.2.1).2bthe 2006 eortc scoring model risk tables predict short- long-term risks disease recurrence progression individual patients nmibc using 1973 classification system (see section 6.1.1.1).1bpatients ta g1/g2 tumours receiving chemotherapy stratified 3 risk groups recurrence, taking account history recurrences, history intravesical treatment, tumour grade (who 1973), number tumours adjuvant chemotherapy (see section 6.1.1.2).2bin patients treated 5 6 months bcg, cueto scoring model predicts short- andlong-term risks disease recurrence progression using 1973 classification system (see section 6.1.1.3).1bin patients receiving least 1 year bcg maintenance; prior recurrence rate number tumours important prognostic factors disease recurrence. stage grade important prognostic factors disease progression disease-specific survival; patient age grade (who 1973) important prognostic factors os (see section 6.1.1.4).1b recommendationsstrength ratingstratify patients 4 risk groups predict progression, according table 6.1. patient’s risk group determined using 2021 eau risk group calculator available www.nmibc.net.strongfor information risk disease progression patient primary tat1 tumours, treated bacillus calmette-guérin (bcg), use data table 6.2.stronguse 2006 eortc scoring model predict risk tumour recurrence individual patients treated bcg.stronguse 2016 eortc scoring model cueto risk scoring model predict risk tumour recurrence individual patients treated bcg intravesical immunotherapy (the 2016 eortc model calculated 1 3 years maintenance, cueto model 5 6 months).strong